Health Economics›Esophageal adenocarcinoma›Metastatic or locally advanced disease subsequent lines of therapy

Metastatic or locally advanced disease subsequent lines of therapy

Esophageal adenocarcinoma · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel and Ramucirumab Variant #01	—	R 98 010	28d	—	9.6 mo	—	—	1
Ramucirumab monotherapy Variant #01	—	R 48 173	14d	—	5.2 mo	—	—	1
Cetuximab monotherapy Variant #04	—	R 29 164	7d	—	~8.1 mo	—	—	3
Irinotecan and Mitomycin Variant #01	—	R 2 896	28d	—	—	—	—	—
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	7.4 mo	—	—	1
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	5.2 mo	—	—	1
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	~2.3 mo	~8.5 mo	~2	~R 95 PFS proxy · indirect	16
Placebo Partial	—	—	—	—	4.7 mo	—	—	1
Irinotecan liposomal monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Best supportive care Partial	—	—	—	~1.7 mo	~4.3 mo	—	—	14
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	5.3 mo	—	—	1
Apatinib monotherapy Variant #01 Partial	—	—	28d	—	6.5 mo	—	—	1

12 of 12 regimens shown